Abstract: Described herein are methods and a system for to optimize utilization of rack space supporting components of an existing client site rack. Real time data as to the rack space is collected, along with an objective function as to expansion. Information as to an initial design configuration is retrieved. A reinforcement learning algorithm processes real time data, the objective function, and initial design configuration to determine a deployment recommendation.

Abstract: A compound includes a polymer associated with a biological agent. The polymer has a first (meth)acryl monomeric unit with a cationic functional group R1 and a second (meth)acryl monomeric unit with a neutral hydrophilic functional group R2. The cationic functional group R1 is chosen from amino groups and alkylamino groups, and the neutral functional group R2 is chosen from polyethylene glycol (PEG), hydroxyl (OH), phosphorylcholine (PC), and mixtures and combinations thereof.

Abstract: Implementations are directed to receiving a first set of event data from a first data source, the first set of event data including data representative of an occurrence of a real-world event, providing an event ticket, the event ticket including at least a portion of data of the first set of event data, transmitting presentation data to one or more computing devices, the presentation data being based on the event ticket and being processable by the computing device to display a real-time view including one or more graphical representations representative of the real-world event, receiving a second set of event data from a second data source, the second set of event data including data associated with the real-world event, revising the event ticket to include at least a portion of data of the second set of event data to provide a revised event ticket, and transmitting revised presentation data to one or more computing devices, the revised presentation data being based on the revised event ticket and being proc

Abstract: A remote care system may include a platform that includes one or more memory devices and one or more processors communicatively coupled to the one or more memory devices. The platform may connect and communicate bi-directionally with a plurality of devices via a gateway device. At least some of the plurality of devices may include sensors capable of gathering vitals data from a patient. The vitals data may include different types of vitals data. The platform may connect and communicate bi-directionally with another plurality of devices. The other plurality of devices may be remote to the gateway device and the at least some of the plurality of devices. The platform may support continuous and live streaming of the vitals data from the sensors. The platform may perform a set of actions on a per patient basis based on analyzing the vitals data.

Abstract: Implementations are directed to receiving a first set of event data from a first data source, the first set of event data including data representative of an occurrence of a real-world event, providing an event ticket, the event ticket including at least a portion of data of the first set of event data, transmitting presentation data to one or more computing devices, the presentation data being based on the event ticket and being processable by the computing device to display a real-time view including one or more graphical representations representative of the real-world event, receiving a second set of event data from a second data source, the second set of event data including data associated with the real-world event, revising the event ticket to include at least a portion of data of the second set of event data to provide a revised event ticket, and transmitting revised presentation data to one or more computing devices, the revised presentation data being based on the revised event ticket and being proc

Abstract: Aspects of the present disclosure include crystalline bazedoxifene free base, crystalline bazedoxifene acetate Form D, and processes for their preparation. The drug compound having the adopted name “bazedoxifene acetate” has a chemical name 1-[4-(2-azepan-1-yl-ethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol acetic acid, and has the chemical structure shown below as Formula I.

Abstract: Aspects of the present disclosure include crystalline bazedoxifene free base, crystalline bazedoxifene acetate Form D, and processes for their preparation. The drug compound having the adopted name “bazedoxifene acetate” has a chemical name 1-[4-(2-azepan-1-yl-ethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol acetic acid, and has the chemical structure shown below as Formula I.